渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 06-12 16:00:00 EDT

200.05

+0.09

+0.05%

盘后200.05

+0.000.00%

18:53 EDT

最高203.45	最低199.06	成交量83.73万
今开200.57	昨收199.96	日振幅2.20%
总市值295.35亿	流通市值292.53亿	总股本1.48亿
成交额1.68亿	换手率0.57%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":200.05,"timestamp":1781294400000,"preClose":199.96,"halted":0,"volume":837293,"hourTrading":{"tag":"盘后","latestPrice":200.05,"preClose":200.05,"latestTime":"18:53 EDT","volume":9283,"amount":1857061.96,"timestamp":1781304791979,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00045009001800361774,"floatShares":146226846,"shares":147637117,"eps":9.296136,"marketStatus":"休市中","change":0.09,"latestTime":"06-12 16:00:00 EDT","open":200.57,"high":203.45,"low":199.06,"amount":167984847.02343002,"amplitude":0.021954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":9.296136,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":199.96,"preHourTrading":{"tag":"盘前","latestPrice":201.46,"preClose":199.96,"latestTime":"09:28 EDT","volume":206,"amount":41500.76,"timestamp":1781270910006,"change":1.5,"changeRate":0.007502,"amplitude":0.009502},"postHourTrading":{"tag":"盘后","latestPrice":200.05,"preClose":200.05,"latestTime":"18:53 EDT","volume":9283,"amount":1857061.96,"timestamp":1781304791979,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8435382073186448,"impliedVol":0.331,"impliedVolPercentile":0.1912},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"1135997390","title":"盘前异动｜绩优股拉升，TTAN、AGX大涨，芯片、光通信概念普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1135997390","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135997390?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:21","pubTimestamp":1780647663,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段涨跌不一。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bbeb5d2aa02322d922b4a6b9f5dbdfec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LULG","BIIB","LULU","TTAN","AGX","LITE","ZUMZ","LITX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640593626","title":"优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2640593626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640593626?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:56","pubTimestamp":1780297012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，优时比和百健周一宣布，双方联合开发的在研药物dapirolizumab pegol在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。BICLA 是一项复合疗效终点指标，用于评估患者所有受累器官系统的疾病活动度是否出现具有临床意义的改善，同时其他狼疮相关病症未发生恶化。安全性方面，该药严重不良事件发生率为 10%，低于安慰剂组的 14.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","BK4533","BK4532","BK4588","LU0320765992.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0109394709.USD","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9P08.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638850232","title":"百健(BIIB.US)MS业务承压：意大利子公司遭反垄断突击检查，被指控滥用检测捆绑销售阻止竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2638850232","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638850232?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:23","pubTimestamp":1779880991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，意大利竞争与市场管理局正式宣布对Biogen Italia及其美国母公司百健启动反垄断调查，指控其涉嫌滥用市场支配地位，通过捆绑一种用于患者安全筛查的医学检测，系统性阻止竞争对手Sandoz的廉价生物类似药进入意大利多发性硬化症治疗市场。百健随后通过电子邮件声明回应称，公司正在\"全力配合当局调查\"，并确认AGCM代表已于周二上午到访其米兰办事处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"百健(BIIB.US)MS业务承压：意大利子公司遭反垄断突击检查，被指控滥用检测捆绑销售阻止竞争","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB","LU0225283273.USD","LU1668664300.SGD","BK4127","LU0557290698.USD","LU0106831901.USD","LU0053666078.USD","LU1720051017.SGD","LU2271345857.HKD","BK4533","LU2347655156.SGD","LU1244550494.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU0314104364.USD","LU1074936037.SGD","BK4504","LU1162221912.USD","BK4139","LU1363072403.SGD","LU1791710582.SGD","LU1732800096.USD","LU2133065610.SGD","BK4588","BK4585","LU2028103732.USD","LU0098860793.USD","LU1244550221.USD","LU1064131342.USD","LU2264538146.SGD","LU1989772840.SGD","LU2357305700.SGD","IE00B19Z9Z06.USD","LU0320765646.SGD","LU0528227936.USD","LU0882574139.USD","LU1988902786.USD","LU2487616109.SGD","LU0795875169.SGD","LU0267386448.USD","LU0971096721.USD","LU0390134368.USD","LU2023251221.USD","LU0210528500.USD","LU1548497426.USD","LU2111349929.HKD","LU0106261372.USD","IE00B894F039.SGD","LU1791710400.SGD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179602120","title":"渤健与Denali Therapeutics公布早期帕金森病药物Biib122（Dnl151）IIb期Luma研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1179602120","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179602120?lang=zh_cn&edition=full","pubTime":"2026-05-22 06:00","pubTimestamp":1779400816,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）与Denali Therapeutics Inc. 近日就双方共同研发的、针对早期帕金森病的在研药物Biib122（亦称Dnl151）的IIb期临床试验（Luma研究）提供了最新进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4535","BK4533","BIIB","BK4548","BK4585","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","BK4532","IE00B19Z9Z06.USD","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717040","title":"阿尔茨海默病新药研发迎曙光！百健(BIIB.US)盘前应声上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717040","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635717040?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:38","pubTimestamp":1778762337,"startTime":"0","endTime":"0","summary":"截至发稿，百健周四美股盘前涨近5%。目前，市场上已有两款获批的阿尔茨海默病治疗药物：由百健与日本制药商卫材合作开发的Leqembi，以及礼来推出的Kisunla。百健Q1业绩打脸悲观预期 阿尔茨海默病药销售暴增74%百健在上月发布的第一季度财报显示，Q1营收同比增长2%至25亿美元，调整后每股收益同比增长18%至3.57美元，双双超出市场平均预期。于2023年获批用于治疗阿尔茨海默病的Leqembi在一季度实现销售额1.68亿美元，同比大增74%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿尔茨海默病新药研发迎曙光！百健(BIIB.US)盘前应声上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4139","BK4588","IE00B19Z9P08.USD","IE00B894F039.SGD","BIIB","LU0320765992.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","BK4533","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104968288","title":"渤健公司盘前股价飙升9.8%，实验性阿尔茨海默病疗法将推进至注册开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1104968288","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104968288?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:20","pubTimestamp":1778757656,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）的股价在盘前交易时段大幅跃升9.8%，其背后驱动力源于该公司宣布将把其一款实验性阿尔茨海默病疗法推进至关键的注册开发阶段。这一决定标志着该疗法研发进程中的重要里程碑，为后续的临床验证和潜在上市铺平了道路。市场对此反应积极，显示出投资者对该疗法前景的浓厚兴趣与期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4533","BK4588","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4585","BIIB","IE00B19Z9Z06.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4532","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146042190","title":"Diranersen (Biib080) II期Celia研究顶线结果：首次显示可降低早期阿尔茨海默病患者Tau病理并带来认知获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1146042190","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146042190?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756496,"startTime":"0","endTime":"0","summary":"Diranersen（研发代号Biib080）的II期Celia研究公布了顶线结果。这项研究在早期阿尔茨海默病患者中，首次证明了该疗法能够减少Tau蛋白病理并带来认知功能的改善。\n研究结果表明，Diranersen治疗显著降低了患者大脑中的Tau蛋白病理负担。同时，接受治疗的患者在认知功能评估中也显示出具有临床意义的获益。这些发现为针对Tau蛋白的阿尔茨海默病疗法提供了重要支持。\n该结果标志着阿尔茨海默病治疗领域的一个重要进展。此前的研究多聚焦于淀粉样蛋白，而此项研究则证实了靶向Tau蛋白同样可能为患者带来实质性益处。这为开发新的治疗策略开辟了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","BK4532","LU0109394709.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4533","BK4588","LU0889565916.HKD","BK4139","BIIB","BK4585","LU0234570918.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132956908","title":"渤健高管称Bib091/多发性硬化症项目“并非再投资”；公司宣称持续研发多发性硬化症BTK抑制剂——美国银行医疗健康会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1132956908","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132956908?lang=zh_cn&edition=full","pubTime":"2026-05-14 02:49","pubTimestamp":1778698167,"startTime":"0","endTime":"0","summary":"在近日举行的美国银行医疗健康会议上，渤健公司高管明确表示，针对Bib091与多发性硬化症（MS）的研发项目“并非一次再投资”。公司同时强调，其在多发性硬化症领域对布鲁顿酪氨酸激酶（BTK）抑制剂的研发工作一直持续进行，未曾中断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4533","BK4588","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4585","BIIB","IE00B19Z9Z06.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4532","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184393788","title":"渤健高管表示：目标不仅是多发性硬化症，更是为更广泛的自身免疫适应症开发具备“恰当获益-风险”特征的BTK抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1184393788","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184393788?lang=zh_cn&edition=full","pubTime":"2026-05-14 02:49","pubTimestamp":1778698154,"startTime":"0","endTime":"0","summary":"渤健公司高管在美银证券医疗健康会议上表示，公司的目标不仅是开发一款用于治疗多发性硬化症的BTK抑制剂，更是要寻求一款具备“恰当获益-风险”特征的产品，并有望将其应用拓展至更广泛的自身免疫疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4533","BIIB","LU0889565916.HKD","LU0320765992.SGD","BK4588","LU0109394709.USD","BK4585","IE00B19Z9Z06.USD","LU0234570918.USD","BK4139","BK4532","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161544025","title":"渤健高管坦言IgAN市场竞争激烈，预计将有“数项”加速审批陆续涌现——美银医疗健康大会见闻","url":"https://stock-news.laohu8.com/highlight/detail?id=1161544025","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161544025?lang=zh_cn&edition=full","pubTime":"2026-05-14 02:46","pubTimestamp":1778697974,"startTime":"0","endTime":"0","summary":"渤健公司高管在美银医疗健康大会上表示，业界普遍承认IgA肾病（IgAN）治疗领域的市场动态已变得相当拥挤。该领域预计将迎来“数项”通过加速审批通道上市的新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4533","BIIB","BK4585","LU0234570918.USD","LU0109394709.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4532","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187026131","title":"渤健公司：评估Leqembi皮下给药临床数据支持Leqembi Iqlik用于初始治疗的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1187026131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187026131?lang=zh_cn&edition=full","pubTime":"2026-05-08 14:33","pubTimestamp":1778222021,"startTime":"0","endTime":"0","summary":"渤健公司表示，评估Leqembi皮下给药方式的临床研究数据为其新型制剂Leqembi Iqlik应用于阿尔茨海默病初始治疗提供了有力依据。最新研究结果显示，该给药方案在维持血药浓度稳定性和患者耐受性方面表现出显著优势，为拓展早期干预治疗方案创造了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4533","BIIB","BK4585","LU0234570918.USD","LU0109394709.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4532","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188757112","title":"FDA对Leqembi® Iqlik™（Lecanemab-Irmb）皮下注射剂作为早期阿尔茨海默病起始剂量的优先审评进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1188757112","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188757112?lang=zh_cn&edition=full","pubTime":"2026-05-08 14:30","pubTimestamp":1778221814,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）正在对Leqembi® Iqlik™（Lecanemab-Irmb）皮下注射剂作为早期阿尔茨海默病起始治疗方案的申请进行优先审评。这一审评决定将影响该药物在临床实践中的应用前景。\n最新进展显示，审评流程正按计划推进。若获得批准，该皮下注射剂型将为患者提供更便捷的给药方式，有望提升治疗依从性。目前，相关数据已提交监管机构进行最终评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","IE00B894F039.SGD","BK4532","BK4588","IE00B19Z9Z06.USD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","BK4139","LU0889565916.HKD","BK4533","IE00B19Z9P08.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133813165","title":"异动解读 | 渤健公司盘中大涨5.25%，第一季度业绩超预期成主要驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=1133813165","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133813165?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:13","pubTimestamp":1777472024,"startTime":"0","endTime":"0","summary":"渤健公司今日盘中股价大幅上涨5.25%，引起了市场的广泛关注。消息面上，渤健公司公布了强劲的第一季度财报，其调整后每股收益及营收均超出市场平均预期，成为推动股价上涨的关键因素。具体来看，公司第一季度调整后每股收益为3.57美元，显著高于分析师预期的2.77美元；营收达到25亿美元，同样超出预期。业绩亮点包括备受市场关注的阿尔茨海默病药物Leqembi销售额同比暴增74%，达到1.68亿美元，有效抵消了多发性硬化症业务面临的部分压力。尽管由于收购相关成本公司下调了全年盈利预期，但出色的季度表现提振了投资者信心，驱动了股价的盘中大涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519083","title":"Leqembi终于“起飞”？百健(BIIB.US)Q1业绩打脸悲观预期，阿尔茨海默病药销售暴增74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631519083?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:18","pubTimestamp":1777465082,"startTime":"0","endTime":"0","summary":"由于近期并购交易产生相关费用，百健下调了全年盈利预期。Leqembi于2023年获批用于治疗阿尔茨海默病，一季度实现销售额1.68亿美元，同比大增74%。若百健能获得美国监管批准，推出更方便居家使用的Leqembi皮下注射新剂型用于阿尔茨海默病患者初始治疗，其销售有望进一步提速。上月，百健同意收购Apellis，从而扩大其在免疫学和罕见病领域的疗法布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BIIB","LU0320765992.SGD","BK4532","IE00B894F039.SGD","BK4533","IE00B19Z9Z06.USD","BK4585","LU0889565916.HKD","LU0109394709.USD","LU0234570918.USD","BK4139","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142617663","title":"渤健公司：尚无法确定Obbba对业务运营及财务状况的整体影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1142617663","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142617663?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:50","pubTimestamp":1777459814,"startTime":"0","endTime":"0","summary":"渤健公司近日表示，目前尚无法准确评估Obbba对其业务运营、经营业绩及财务状况可能产生的整体影响。该公司在声明中指出，相关影响的具体程度和范围仍存在不确定性，需要进一步观察和评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0320765992.SGD","BK4532","BK4139","LU0889565916.HKD","BK4588","LU0234570918.USD","BIIB","IE00B894F039.SGD","LU0109394709.USD","BK4533","IE00B19Z9Z06.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153383624","title":"渤健公司发布年度业绩展望：调整后每股收益14.25-15.25美元 略低于市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153383624","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153383624?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:18","pubTimestamp":1777457907,"startTime":"0","endTime":"0","summary":"渤健公司最新财报显示，第一季度调整后每股收益达3.57美元，显著超越市场预期的2.77美元。同时，该公司第一季度营收实现24.8亿美元，同样高于分析师预测的22.5亿美元。\n在年度业绩展望方面，渤健预计全年调整后每股收益将在14.25至15.25美元区间，而根据LSEG IBES数据，市场普遍预期为15.04美元。值得关注的是，这份年度指引中包含了因收购无形资产研发项目带来的每股约1美元的影响。\n展望2026年，公司预计营收将出现中个位数百分比的下滑，全年营收预期为98.4亿美元。渤健公司表示，将在第二季度财报发布时提供包含对Apellis收购交易的最新2026年度业绩指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0320765992.SGD","BK4532","BK4139","LU0889565916.HKD","BK4588","LU0234570918.USD","BIIB","IE00B894F039.SGD","LU0109394709.USD","BK4533","IE00B19Z9Z06.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186227403","title":"财报前瞻｜渤健公司本季度营收预计增0.78%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1186227403","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186227403?lang=zh_cn&edition=full","pubTime":"2026-04-22 11:05","pubTimestamp":1776827137,"startTime":"0","endTime":"0","summary":"渤健公司将于2026年04月29日美股盘前发布最新季度财报，市场聚焦盈利修复节奏与管线推进对收入结构的影响。市场一致预期本季度渤健公司营收为22.51亿美元，同比约增长0.78%；调整后每股收益为3.01美元，同比约增长19.28%；息税前利润为5.40亿美元，同比约增长11.37%，公司层面未看到关于毛利率与净利率的明确指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜渤健公司本季度营收预计增0.78%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197564615","title":"Alloy与渤健达成合作：借助技术平台推进多个未公开靶点的反义疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1197564615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197564615?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:02","pubTimestamp":1775556134,"startTime":"0","endTime":"0","summary":"Alloy Therapeutics近日宣布与生物技术巨头渤健公司达成战略合作。根据协议内容，渤健将利用Alloy特有的技术平台，加速针对多个未公开靶点的反义寡核苷酸疗法研发进程。此次合作将充分发挥双方在药物研发领域的专业优势，通过平台化技术手段提升治疗方案的开发效率。\n反义疗法作为精准医疗的重要分支，通过特异性调节基因表达来治疗疾病。此次合作涉及的多个靶点虽未公开具体信息，但双方表示将聚焦于存在重大未满足临床需求的疾病领域。业内观察人士指出，这种平台化合作模式有望为创新疗法研发提供新的范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4533","BK4585","BK4588","LU0320765992.SGD","LU0889565916.HKD","IE00B894F039.SGD","BIIB","LU0234570918.USD","BK4532","BK4139","IE00B19Z9Z06.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149102155","title":"渤健公司同意以56亿美元收购Apellis Pharmaceuticals，股价跌至1月以来最低点，日内跌幅达7.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149102155","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149102155?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:33","pubTimestamp":1774963995,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）股价遭遇重挫，在宣布将以56亿美元收购Apellis Pharmaceuticals Inc.后，盘中跌幅一度扩大至7.7%，创下自今年1月以来的最低水平。此次收购协议引发市场对渤健公司财务负担和整合前景的担忧，投资者纷纷抛售股票，导致其股价承压下行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4139","BK4533","BK4532","BK4588","APLS","LU0320765992.SGD","LU1093756168.USD","LU0234570918.USD","LU1093756325.SGD","IE00B19Z9Z06.USD","LU0109394709.USD","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9P08.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858686","title":"Apellis(APLS)盘前涨超142% Biogen(BIIB)将以56亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623858686?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:31","pubTimestamp":1774956713,"startTime":"0","endTime":"0","summary":"金吾财讯| Apellis Pharmaceuticals(APLS)盘前涨超142%，每股报41.05美元。消息面上，Biogen Inc.已同意以56亿美元收购Apellis Pharmaceuticals Inc.，扩大其在免疫学和罕见病领域的治疗能力，这是该公司有史以来规模最大的收购之一。该公司将以每股41美元的价格收购Apellis，是后者周一收盘价的两倍多。通过这笔交易，Biogen将获得两种已获批准的药物。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298590","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B894F039.SGD","LU0234570918.USD","LU1093756325.SGD","LU0889565916.HKD","APLS","BK4505","BK4139","LU0320765992.SGD","BIIB","BK4585","BLLB","IE00B19Z9P08.USD","BK4588","LU1093756168.USD","IE00B19Z9Z06.USD","BK4532","BK4533"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com;investors.biogen.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":-0.0219},{"period":"3month","weight":0.1019},{"period":"6month","weight":0.1491},{"period":"1year","weight":0.512},{"period":"ytd","weight":0.1367}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性生物制药公司，致力于为患有严重复杂疾病的人发现、开发和提供创新疗法。该公司拥有广泛的多发性硬化症（MS）药物组合，推出了首个获批治疗脊髓性肌萎缩症（SMA）的药物，共同开发了解决阿尔茨海默病定义病理学的治疗方法，并推出了首个获批的针对肌萎缩侧索硬化症（ALS）遗传原因的疗法。渤健还销售第一个也是唯一一个批准用于治疗16岁及以上成人和青少年的弗里德赖希共济失调（FA）的药物。其研发工作专注于神经病学、专业免疫学和罕见病，并得到内部项目、合作和收购的支持。该公司将生物制剂和生物仿制药商业化，并与领先的制药公司保持战略合作伙伴关系，以推进其产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.00281},{"month":3,"riseRate":0.485714,"avgChangeRate":-0.023881},{"month":4,"riseRate":0.342857,"avgChangeRate":-0.019659},{"month":5,"riseRate":0.628571,"avgChangeRate":0.03345},{"month":6,"riseRate":0.485714,"avgChangeRate":0.016713},{"month":7,"riseRate":0.676471,"avgChangeRate":0.034715},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}